ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES

ODay K.; Runken M. C.; Meyer K. L.; Spears J. B.

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES

【24h】

ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES

机译：治疗严重血友病患者血浆衍生因子-VIII / VWF与美国重组因子 - VIII患者的经济影响

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2017年第5期|共2页
作者
ODay K.; Runken M. C.; Meyer K. L.; Spears J. B.;
展开▼
作者单位

Xcenda LLC Palm Harbor FL USA;

Grifols Inc Res Triangle Pk NC USA;

Xcenda LLC Palm Harbor FL USA;

Grifols Inc Res Triangle Pk NC USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES [J] . ODay K., Runken M. C., Meyer K. L., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：治疗严重血友病患者血浆衍生因子-VIII / VWF与美国重组因子 - VIII患者的经济影响
2. High-titre inhibitors in previously untreated patients with severe hemophilia A: an updated estimate of pooled incidence rates in patients treated with plasma-derived concentrates or recombinant Factor VIII [J] . A. Messori, V. Fadda, D. Maratea, Drugs and Cell Therapies in Hematology . 2013,第3期

机译：先前未经治疗的严重血友病患者中的高滴度抑制剂：血浆衍生浓缩物或重组凝血因子VIII治疗的患者合并发生率的最新估计
3. Rates of inhibitor development in previously untreated patients with severe hemophilia a treated with plasma-derived or recombinant factor VIII: No proof of difference or proof of no difference? [J] . MessoriA., FaddaV., MarateaD., Seminars in Thrombosis and Hemostasis . 2014,第2期

机译：在先前未经治疗的严重血友病患者中用血浆来源的或重组的凝血因子VIII治疗的抑制剂发生率：无差异证据或无差异证据？
4. Factor VllhC Measurement - Comparison between chromogenic and coagulometric Methods in Hemophilia A-Patients with the B-Domain depleted recombinant F VIII-Preparation ReFacto [C] . A. Siegemund, T. Siegemund, U. Scholz, Hemophilie-Symposion . 2003

机译：因子VLLHC测量 - 血友病患者血友病患者的色情和凝血法的比较鉴定重组F VIII制剂refacto
5. Satisfaction, Adherence, and Recombinant Factor VIII Choice of Patients with Moderate to Severe Hemophilia A [D] . Strickland, Kimberly. 2020

机译：满意度，依从性和重组因素VIII患者中度至重度血友病的患者
6. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective [O] . Gary Benson, Tim Morton, Huw Thomas, 2021

机译：先前治疗的成人和青春期患者的长期结果是严重血友病药物接受预防延长半衰期FVIII治疗：来自英国视角的经济分析
7. Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference? [O] . Andrea Messori, Valeria Fadda, Dario Maratea, 2014

机译：抑制剂发育中以前未经处理的血浆血糖A或重组因子viii治疗的患者的抑制率：没有差异的证据或无差别证明？

ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES

著录项

相似文献

相关主题

期刊订阅